229 related articles for article (PubMed ID: 27194941)
1. In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells.
Zhou Q; Chen Y; Chen X; Zhao W; Zhong Y; Wang R; Jin M; Qiu Y; Kong D
Int J Biol Sci; 2016; 12(6):631-8. PubMed ID: 27194941
[TBL] [Abstract][Full Text] [Related]
2. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
4. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
[TBL] [Abstract][Full Text] [Related]
5. In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells.
Zhang L; Wang Z; Khishignyam T; Chen T; Zhou C; Zhang Z; Jin M; Wang R; Qiu Y; Kong D
Biomed Pharmacother; 2018 Jul; 103():1069-1078. PubMed ID: 29710665
[TBL] [Abstract][Full Text] [Related]
6. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D
Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649
[TBL] [Abstract][Full Text] [Related]
7. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells.
Zhou Q; Chen Y; Zhang L; Zhong Y; Zhang Z; Wang R; Jin M; Gong M; Qiu Y; Kong D
Oncotarget; 2017 Jun; 8(24):39064-39076. PubMed ID: 28388564
[TBL] [Abstract][Full Text] [Related]
9. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
Guerra B; Martín-Rodríguez P; Díaz-Chico JC; McNaughton-Smith G; Jiménez-Alonso S; Hueso-Falcón I; Montero JC; Blanco R; León J; Rodríguez-González G; Estévez-Braun A; Pandiella A; Díaz-Chico BN; Fernández-Pérez L
Oncotarget; 2017 May; 8(18):29679-29698. PubMed ID: 27557509
[TBL] [Abstract][Full Text] [Related]
10. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
11. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
[TBL] [Abstract][Full Text] [Related]
13. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
[TBL] [Abstract][Full Text] [Related]
14. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
16. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
17. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
18. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.
Lompardía SL; Díaz M; Papademetrio DL; Pibuel M; Álvarez É; Hajos SE
Invest New Drugs; 2017 Feb; 35(1):1-10. PubMed ID: 27718039
[TBL] [Abstract][Full Text] [Related]
19. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
Mukai M; Che XF; Furukawa T; Sumizawa T; Aoki S; Ren XQ; Haraguchi M; Sugimoto Y; Kobayashi M; Takamatsu H; Akiyama S
Cancer Sci; 2003 Jun; 94(6):557-63. PubMed ID: 12824882
[TBL] [Abstract][Full Text] [Related]
20. Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL.
Wang CG; Zhong L; Liu YL; Shi XJ; Shi LQ; Zeng L; Liu BZ
Integr Cancer Ther; 2017 Dec; 16(4):526-539. PubMed ID: 27698265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
